Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, Follicular 5Recurrence 3Hereditary Sensory and Autonomic Neuropathies 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Leukemia 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Lymphoma, T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Immunoblastic Lymphadenopathy 1Head and Neck Neoplasms 1Advanced Solid Tumors 1

Interventions

Rituximab 23Lenalidomide 11Cyclophosphamide 10zanubrutinib 9Bendamustine Hydrochloride 8venetoclax 6ibrutinib 6fludarabine 6parsaclisib 5idelalisib 5ublituximab 4obinutuzumab 4aflibercept 4Prednisone 4pirtobrutinib 3Vincristine 3ME-401 3Doxorubicin 3umbralisib 2tazemetostat 2marizomib 2epratuzumab 2Radioimmunodetection 2voruciclib 1veltuzumab 1varlilumab 1tislelizumab 1tetulomab tetraxetan lu-177 1tafasitamab 1repaglinide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, B-Cell, Marginal Zone × duvelisib × Clear all
NCT02576275 2021-03-17

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

SecuraBio

Phase 3 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡